You can read RaaS Group's 25 page AML3D Initiation Report here.
It includes, "...Negative free cashflow was reported in 2021 and is expected in 2022 and 2023. We expect strong free cash generation thereafter. Using a WACC of 11.1% (Beta 1.5 vs measured Beta of 0.21, terminal growth rate of 2.2%) we derive an equity value of $71m or $0.475/share on the current issued capital of 150.4m shares..."
- Forums
- ASX - By Stock
- AL3
- RE: Report
RE: Report, page-3
Featured News
Add AL3 (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.5¢ |
Change
-0.030(12.2%) |
Mkt cap ! $81.50M |
Open | High | Low | Value | Volume |
24.0¢ | 24.0¢ | 21.0¢ | $590.8K | 2.689M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 239137 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 124444 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 239137 | 0.215 |
10 | 169235 | 0.210 |
6 | 340300 | 0.205 |
12 | 641174 | 0.200 |
3 | 1640000 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 124444 | 4 |
0.225 | 380000 | 4 |
0.230 | 126801 | 5 |
0.235 | 27225 | 2 |
0.240 | 207413 | 6 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
AL3 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online